Research Article

Clinical Value of Preoperative Ultrasound Signs in Evaluating Axillary Lymph Node Status in Triple-Negative Breast Cancer

Jundong Wang, Xiaoli Lu, Xuan Zheng, Congyan Xia, and Ping Li

Department of Ultrasound, Nanjing First Hospital, Jiangsu Province, China

Correspondence should be addressed to Ping Li; guwenping2008@163.com

Received 7 March 2022; Revised 10 April 2022; Accepted 11 April 2022; Published 14 May 2022

Academic Editor: Dong-Hua Yang

Purpose. To explore the clinical value of preoperative ultrasound signs in evaluating axillary lymph node status in triple-negative breast cancer (TNBC). Methods. A retrospective study was conducted on 162 patients with TNBC who were admitted to our hospital from January 2017 to June 2021. A total of 62 patients with axillary lymph node metastasis and 100 patients with normal axillary lymph nodes were included. Univariate and logistic regression was used to analyze the correlation between clinicopathological parameters, ultrasound features, and axillary lymph node metastasis between these two groups. The receiver operating characteristic (ROC) curve of each index was drawn to predict positive axillary lymph node. Results. The lymph node positive rate was higher in patients with tumor size ($T \leq 5$ mm) and tumor stage III, and the difference between these two groups was statistically significant ($P < 0.05$). The patients with cortical thickness $\geq 3$, blood flow grades II-III, aspect ratio (L/S) $\geq 2$, and RI $\geq 0.7$ had higher lymph node positive rate, and the difference between these two groups was statistically significant ($P < 0.05$). Other index shows no correlation with ancillary lymph node positive rate, or the correlation was not statistically significant ($P > 0.05$). Further regression analysis indicated that the blood flow grade and L/S of axillary lymph nodes were independent influencing factors of axillary lymph node metastasis in TNBC patients ($P < 0.05$). Relevant receiver operating characteristic (ROC) curves were constructed, and the AUC of axillary lymph node blood flow grade and L/S for predicting axillary lymph node status was 0.6329 and 0.6498, respectively. The AUC for the joint prediction of the two indicators is 0.6898. Conclusion. Ultrasound sign combined with clinicopathological characteristics can predict the axillary lymph nodes metastasis in TNBC, which could guide clinical decision of axillary lymph node surgery.

1. Introduction

Breast cancer seriously threatens the health of women. At present, the incidence of breast cancer is increasing every year and in younger population. Some studies have reported that the number of breast cancer in women under the age of 40 years old continues to increase, and about 11% of the new patients are not older than 45 years old, which has become a public health concern [1]. Axillary lymph nodes are the most common metastatic sites of breast cancer, accounting for about 75% of total metastasis of breast cancer. Axillary lymph node metastasis is the most important predictor of recurrence of the tumor and survival rate for the breast cancer patients. Studies have shown that the 5-year survival rate of patients with axillary lymph node metastasis is about 85.8% [2]. For patients with axillary lymph node metastasis, axillary lymph node dissection can improve the survival rate. However, for breast cancer patients with no axillary lymph node metastasis confirmed by postoperative pathological results, axillary lymph node dissection has no therapeutic effect. Therefore, accurate preoperative assessment of axillary lymph node status is important for breast cancer staging and clinical decisions for appropriate treatment.

Currently, almost all breast cancer patients undergo sentinel node biopsy to determine the status of the axillary lymph nodes. However, studies have demonstrated that more than 60% of patients with early-stage breast cancer are confirmed to be node-negative via pathological examination who are not benefit from sentinel lymph node
biopsy. Therefore, whether a noninvasive assessment method of axillary lymph node status can replace sentinel node biopsy or fine-needle aspiration biopsy (FNAC) increasing attention, preoperative axillary ultrasound is routinely used in clinical practice, and metastatic axillary lymph nodes have certain characteristics on ultrasound images. However, guidelines, consensus, and diagnostic criteria for assessing the status of axillary lymph nodes using ultrasound are inadequate, which makes the results of ultrasound assessment of axillary lymph nodes controversial. Moreover, the differences in operator experience and the resolution of ultrasound instruments reduced the accuracy of ultrasound in detecting metastatic lymph node. Several studies are also currently investigating whether axillary ultrasonography can replace sentinel point biopsy in patients with CT1N0 breast cancer [3, 4].

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast tumors and lacks estrogen receptors, progesterone receptors, and human epidermal growth factor receptors [5, 6]. TNBC accounts for 15% to 20% of all breast cancer incidences. Compared with other breast cancer subtypes, TNBC usually has larger mass, higher lymph node positive rate, aggressiveness, recurrence rate, and poor prognosis [7, 8]. At present, there are few studies on the influencing factors of ultrasound on axillary lymph node metastasis of TNBC. This article is aimed at exploring the influencing factors of ultrasound in diagnosing lymph node metastasis in TNBC, predicting the metastasis of axillary lymph nodes, and selecting the surgical plan for axillary lymph nodes.

2. Material and Method

2.1. Study Subjects. This is a retrospective study on 162 TNBC patients who were admitted to Nanjing First Hospital from January 2017 to June 2021, aged 27-78 years, with an average of 48.39 ± 10.83 years old. All enrolled patients signed informed consents. The patients’ demographics are shown in Table 1. Inclusion criteria were as follows: (1) female patients diagnosed with breast cancer by surgery and pathology; (2) patients with negative ER, PR, and HER-2 in postoperative immunohistochemical or fluorescence in situ hybridization (FISH) examinations; and (3) patients with clear preoperative ultrasound images and complete data. Exclusion criteria were as follows: (1) patients who received breast cancer surgery, chemotherapy, radiotherapy, and other treatments before surgery and (2) patients who did not sign the informed consent form or did not agree to be enrolled.

3. Methods of Examination

3.1. Ultrasound Examination. The color Doppler ultrasound diagnostic instrument used for ultrasound examination is MyLab Twice (Esaote Company, Italy). The frequency of the linear array probe was 4-13 MHz. The ultrasound images of the patients were reviewed and analyzed by 2 experienced sonographers. If difference in diagnosis occurred, an agreement was reached after discussion. All patients were examined according to the 2019 edition of the Chinese Society of Clinical Oncology (CSCO) guidelines and the 2013 edition of the American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS). The patient was placed in the supine or lateral position, and the bilateral arms were abducted and raised to fully expose the bilateral breasts and axillae. The location, number, size, boundary, morphology, internal echo, calcification of lymph nodes, cortical thickness, aspect ratio (L/S), and resistance index (RI) were measure and recorded. The clear two-dimensional images were stored. Any one of the following conditions is considered abnormal lymph node status: (1) spherical shape and/or L/S enlargement, (2) disappearance of lymphatic hilum structure, (3) abnormal blood flow signal detected by color Doppler Adler grading, and (4) eccentric thickening and interruption of the lymph node cortex.

3.2. Ultrasonography-Guided Fine Needle Aspiration Cytology (FNAC) of the Lymph Nodes. In this study, 64 patients with positive lymph nodes underwent ultrasound-guided fine needle aspiration cytology. Before aspiration, ultrasound positioning was performed to determine the aspiration point, and a 10 ml empty needle was injected into the suspected positive lymph node under ultrasound guidance. To confirm whether the needle tip is located in the suspicious lymph node, several times of advancing, retreating, and rotating were performed to obtain enough tissue. The aspirated tissue was smear for cytology.

3.3. Lymph Node Biopsy. All the included patients underwent sentinel lymph node biopsy. The sentinel lymph nodes

| Subject                               | n   | %     |
|---------------------------------------|-----|-------|
| Age (years)                           |     |       |
| <48                                   | 82  | 50.62 |
| ≥48                                   | 80  | 49.38 |
| Family history of breast cancer       |     |       |
| Yes                                   | 11  | 6.79  |
| No                                    | 151 | 93.21 |
| Tumor size                            |     |       |
| T1 (T < 2)                            | 25  | 15.43 |
| T2 (2 < T ≤ 5)                        | 104 | 64.20 |
| T3 (5 < T)                            | 33  | 20.37 |
| Axillary lymph node status            |     |       |
| Positive                              | 62  | 38.27 |
| Negative                              | 100 | 61.73 |
| Histology                             |     |       |
| Ductal                                | 143 | 88.27 |
| Lobular                               | 12  | 7.41  |
| Others                                | 7   | 4.32  |
| Ki67                                  |     |       |
| ≤14                                   | 14  | 8.64  |
| >14                                   | 148 | 91.36 |

Table 1: Baseline information of the patients.
were detected using the dye and radionuclide double tracer method based on the following surgical guidelines: (1) the radionuclide tracer is 99mTc-labeled sulfur colloid, which is injected into the gland layer in the areola region 6 and 9 o’clock point of the affected side within 3-18 hours before the surgery. Ultrasound guidance was applied to ensure the injection depth during injection. Both sides are injected in the same way. (2) The blue dye is methylene blue, which is injected 10-15 minutes before surgery around the tumor or in the areola of the affected side. During surgery, the sentinel lymph node biopsy was performed first, and the first blue-stained lymph node entered by the blue-stained lymphatic vessel was searched at the level of the anterior axillary line. Then, using the radionuclide method, the γ detector was used to search for the radionuclide-concentrated lymph nodes in the axilla. All lymph nodes that exceeded the maximum lymph node count by 10% are sentinel lymph nodes. After the sentinel lymph nodes were detected by the dye and radionuclide double tracer, the axilla was palpated. Surgical specimens were sent for routine pathological examination. The postoperative sentinel lymph node and axillary lymph node biopsy results were taken as the gold standard to calculate the true and false positive rate of axillary ultrasonography, FNAC, and both methods combined.

### Table 2: Accuracy of different methods assessing the axillary lymph node status.

| Method       | N   | True positive rate (%) | False positive rate (%) | False negative rate (%) |
|--------------|-----|------------------------|-------------------------|-------------------------|
| Ultrasound   | 162 | 91.94                  | 7.00                    | 8.06                    |
| FNAC         | 64  | 85.96                  | 0.00                    | 14.04                   |

### Table 3: Correlation between clinicopathological features and axillary lymph node metastasis.

| Subject                     | Axillary lymph node status | N | Positive | Negative | $\chi^2$ | $P$  |
|-----------------------------|---------------------------|---|----------|----------|----------|-------|
| Age (years)                 |                           |   | 62       | 100      |          |       |
| <48                         | 33                        | 49| 0.2734   | 0.6011   |          |       |
| ≥48                         | 29                        | 51|          |          |          |       |
| Family history of breast cancer |                         |   |          |          | 2.016   | 0.1556 |
| Yes                         | 2                         | 9 |          |          |         |       |
| No                          | 60                        | 91|          |          |         |       |
| Tumor size                  |                           |   |          |          | 29.33   | <0.0001|
| $T_1$ (T < 2 mm)            | 1                         | 24|          |          |         |       |
| $T_2$ (2 mm < T ≤ 5 mm)     | 37                        | 67|          |          |         |       |
| $T_3$ (5 mm < T)            | 24                        | 9 |          |          |         |       |
| Histology                   |                           |   |          |          |         |       |
| Ductal                      | 58                        | 85|          |          | 2.916   | 0.2327 |
| Lobular                     | 3                         | 9 |          |          |         |       |
| Others                      | 1                         | 6 |          |          |         |       |
| Ki67                        |                           |   | 3        | 11       | 1.840   | 0.1749 |
| ≤14                         | 59                        | 89|          |          |         |       |
| >14                         | 5                         | 9 |          |          |         |       |

### 3.4. Statistical Analysis.

Statistical analysis was performed using SPSS 22.0 and GraphPad Prism 6. The count data between groups were compared by the $c^2$ test or Fisher’s exact probability method. The statistically significant
Table 4: Correlation between ultrasound signs and axillary lymph node metastasis.

| Subject                      | Positive (N = 62) | Negative (N = 100) | $\chi^2$ | P     |
|------------------------------|-------------------|--------------------|---------|-------|
| Quadrant                     |                   |                    |         |       |
| Upper-outside                | 32                | 52                 | 1.287   | 0.8637|
| Lower-outside                | 11                | 17                 |         |       |
| Lower-inside                 | 2                 | 5                  |         |       |
| Lower-outside                | 10                | 18                 |         |       |
| Other                        | 8                 | 8                  |         |       |
| Cortical thickness (mm)      |                   |                    |         |       |
| <2                           | 11                | 34                 | 5.290   | 0.0214|
| ≥2                           | 52                | 66                 |         |       |
| Internal echo                |                   |                    |         |       |
| Homogeneous                  | 9                 | 12                 | 0.2148  | 0.6431|
| Heterogeneous                | 53                | 88                 |         |       |
| Margin                       |                   |                    |         |       |
| Smooth                       | 14                | 34                 | 2.916   | 0.2327|
| Not smooth                   | 48                | 66                 |         |       |
| Shape                        |                   |                    |         |       |
| Regular                      | 8                 | 21                 | 0.2908  | 0.5897|
| Irregular                    | 54                | 79                 |         |       |
| Parallel to the skin         |                   |                    |         |       |
| Yes                          | 34                | 57                 | 0.0726  | 0.7876|
| No                           | 28                | 43                 |         |       |
| Calcification                |                   |                    |         |       |
| Yes                          | 25                | 35                 | 0.4649  | 0.4953|
| No                           | 37                | 65                 |         |       |
| Blood flow grade             |                   |                    |         |       |
| 0-I                          | 17                | 64                 | 20.49   | <0.0001|
| II-III                       | 45                | 36                 |         |       |
| Posterior                    |                   |                    |         |       |
| No change                    | 39                | 69                 | 2.897   | 0.4078|
| Deterioration                | 6                 | 14                 |         |       |
| Enhancement                  | 9                 | 8                  |         |       |
| Mixed                        | 8                 | 9                  |         |       |
| L/S                          |                   |                    |         |       |
| <2                           | 18                | 59                 | 13.78   | 0.0002|
| ≥2                           | 44                | 41                 |         |       |
| RI                           |                   |                    |         |       |
| <0.7                         | 51                | 94                 | 5.618   | 0.0178|
| ≥0.7                         | 11                | 6                  |         |       |

Table 5: Logistic regression analysis.

| Subject           | B (beta, mean regression coefficient) | Std. error | Wald (chi-square value) | Degree of freedom (df) | P     | OR    |
|-------------------|--------------------------------------|------------|-------------------------|-----------------------|-------|-------|
| Tumor size        | 0.7927                               | 0.4240     | 3.496                   | 1                     | 0.0615| 2.209 |
| Cortical thickness| 0.2532                               | 0.3815     | 0.4406                  | 1                     | 0.5068| 1.288 |
| Blood flow grade  | 1.217                                | 0.3730     | 10.65                   | 1                     | 0.0011| 3.378 |
| L/S               | 1.306                                | 0.3674     | 12.64                   | 1                     | <0.0001| 3.692 |
| RI                | 0.5007                               | 0.5798     | 0.7456                  | 1                     | 0.3879| 1.6498|
differences were analyzed by multivariate logistic regression analysis, and the ROC curve of the relevant indicators to predict the status of axillary lymph nodes was drawn. \( P < 0.05 \) was considered to be of statistical significance.

4. Result

4.1. Ultrasound Signs for Axillary Lymph Node Status. The negative ultrasound sign of lymph nodes was those with no obvious abnormal lymph node images as shown in Figures 1(a) and 1(b). Ultrasound described as a 20 mm\(^{+}\) 10 mm hypoechoic mass in the axilla with clear boundary and regular shape and a wide door-like structure inside with no obvious calcification and no change in the posterior echo. The blood flow was graded as grade 0. No obvious signs of metastasis were seen.

The positive lymph nodes are shown in Figures 1(c) and 1(d). Ultrasound described a 20.2 mm\(^{+}\) 8.7 mm\(^{+}\) hypoechoic mass in the axilla, with irregular shape, unclear boundary, and no door-like structure. The blood flow grade was grade III.

4.2. Comparison of Ultrasound and FNAC for Assessment of Axillary Lymph Node Status. The true positive rate of ultrasound assessment of axillary lymph node status was 91.94\%, which was higher than that of FNAC (85.96\%); the false negative rate of ultrasound assessment of axillary lymph node status was 8.06\%, lower than that of cell biopsy (14.04\%). The false positive rate of ultrasound assessment of axillary lymph node status was 7.00\%, which was higher than that of FNAC (0.00\%) (Table 2).

4.3. Correlation between Clinicopathological Features and Axillary Lymph Node Metastasis. The lymph node positive rate was higher in patients with tumor size (2 mm < \( T \leq 5 \) mm) and tumor stage III. The difference between groups was statistically significant (\( P < 0.05 \). There was no significant difference in age, family history, histological type, and Ki67 proliferation index between groups (\( P > 0.05 \)) (Table 3).

4.4. Correlation of Ultrasound Signs with Axillary Lymph Node Metastases. The patients with cortical thickness \( \geq 3 \), blood flow grades II-III, \( \text{L/S} \geq 2 \), and RI \( \geq 0.7 \) had higher lymph node positive rate. The difference between groups was statistically significant (\( P < 0.05 \)). There was no significant difference between the other groups (\( P > 0.05 \)) (Table 4).

4.5. Logistic Regression Analysis. The blood flow status and \( \text{L/S} \) of axillary lymph nodes were independent influencing factors of TNB axillary lymph node metastasis (\( P < 0.05 \)). For patients with blood flow grades II-III, the risk of axillary lymph node (+) is 3.378 times that of blood flow grades 0-I; in patients with \( \text{L/S} \geq 2 \), the risk of axillary lymph node (+) was 3.692 times that of \( \text{L/S} < 2 \) (Table 5 and Figure 2).

4.6. ROC Curve. The AUC of axillary lymph node blood flow grade and \( \text{L/S} \) for predicting the status of axillary lymph nodes were 0.6329 and 0.6498, respectively, and the AUC of the combined prediction was 0.6898 (Table 6, Figure 3).

5. Discussion

Axillary lymph nodes are the most common metastatic site of breast cancer. The status of axillary lymph nodes is often used to guide the treatment and prognosis of breast cancer patients before surgery. TNBC is a highly heterogeneous breast tumor. Compared with other subtypes of breast cancer, TNBC is more sensitive to chemotherapy, but has strong invasiveness and rapid progression, and is more prone to lymph node metastasis. Some studies have reported that more than 30\% of TNBC patients have positive axillary lymph nodes [9]. Therefore, it is very important to accurately assess the status of axillary lymph nodes in TNBC patients. Currently, the status of axillary lymph nodes in patients with TNBC can be assessed by imaging examinations, FNAC, and sentinel lymph node biopsy. Axillary lymph node dissection can also clarify the status of lymph nodes, but it will bring complications such as upper limb edema, and it has been gradually replaced by sentinel lymph node biopsy. Yet, sentinel lymph node biopsy still has a certain false negative rate, and its standard includes radionuclide imaging, which is high cost and requires radiation.

With the rapid development of imaging-related technologies, imaging-assisted examination including ultrasound, mammography, computerized tomography, and magnetic resonance imaging is widely used in the diagnosis of axillary lymph node metastasis. The above several imaging-assisted examination methods have their own advantages and disadvantages. Compared with other methods, ultrasound is recommended by many researchers because of its high diagnostic rate, noninvasiveness, lower cost, easy operation, and real-time detection [3, 10, 11]. At present, many studies evaluated the relationship between the axillary lymph node

Table 6: ROC curve-related parameters of each index predicting axillary lymph node status.

| Subject          | AUC    | Std. error | 95\% CI       | \( P \) |
|------------------|--------|------------|---------------|--------|
| Blood flow grade | 0.6329 | 0.0446     | 0.5453-0.7203 | 0.0045 |
| \( \text{L/S} \) | 0.6498 | 0.0442     | 0.5631-0.7366 | 0.0014 |
| Combination      | 0.6898 | 0.0431     | 0.6053-0.7744 | <0.0001 |
ultrasound characteristics and the properties of axillary lymph nodes. Some research reported that the L/S of axillary lymph nodes is of great significance for judging metastasis of axillary lymph nodes [12, 13]. Some researchers believe that disappearance of lymph node hilum is helpful for judging metastasis of lymph nodes. Additionally, the thickened lymph node cortex and the change of vascular pattern of the lymph node are both critical sign lymph node metastasis. Previous studies using ultrasound signs to predict axillary lymph node status reported that the sensitivity of axillary ultrasound can reach 76%, and the negative prediction rate can reach 89% [14]. Du et al. [15] reported that the morphology and blood flow grading of axillary lymph nodes in ultrasound signs were independent influencing factors for predicting lymph node metastasis. Luo et al. [12] constructed an ROC curve for predicting axillary lymph node metastasis. Its AUC reached 0.75 (95% CI: 0.70-0.79) and 0.91 (95% CI: 0.84-0.97), indicating a reliable predictive ability. Thus, analyzing the correlation between ultrasound features and axillary lymph node metastatic status and developing a predictive model based on these features will have clinical values.

This study focused on the relationship between the diagnosis of breast cancer axillary lymph node metastases and its characteristics of ultrasonography. The results might be biased due to different sonographers and different instrument resolutions. In addition, this study is a retrospective study, and it is difficult to collect complete clinical data of patients. These factors may have an impact on the results, and further studies are warranted.

In conclusion, the characteristics of ultrasound images combined with clinicopathological characteristics can predict the metastasis of axillary lymph nodes in TNBC patients with high prediction efficiency. Preoperative ultrasound signs could help clinical decisions for axillary lymph node surgery.

**Data Availability**

Emails could be sent to the address below to obtain the shared data: guwenping2008@163.com.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] L. Rossi, C. Mazzara, and O. Pagani, “Diagnosis and treatment of breast cancer in young women,” *Current Treatment Options in Oncology*, vol. 20, no. 12, p. 86, 2019.
[2] J. M. Chang, J. W. T. Leung, L. Moy, S. M. Ha, and W. K. Moon, “Axillary nodal evaluation in breast cancer: state of the art,” Radiology, vol. 295, no. 3, pp. 500–515, 2020.

[3] D. Liu, X. Li, Y. Lan et al., “Models for predicting sentinel and non-sentinel lymph nodes based on pre-operative ultrasonic breast imaging to optimize axillary strategies,” Ultrasound in Medicine & Biology, vol. 47, no. 11, pp. 3101–3110, 2021.

[4] T. Reimer, A. Stachs, V. Nekljudova et al., “Restricted axillary staging in clinically and sonographically node-negative early invasive breast cancer (c/iT1-2) in the context of breast-conserving therapy: first results following commencement of the intergroup-sentinel-mamma (INSEMA) trial,” Geburtshilfe und Frauenheilkunde, vol. 77, no. 2, pp. 149–157, 2017.

[5] E. Vagia, D. Mahalingam, and M. Cristofanilli, “The landscape of targeted therapies in TNBC,” Cancers, vol. 12, no. 4, p. 916, 2020.

[6] M. Shen, H. Pan, Y. Chen, Y. H. Xu, W. Yang, and Z. Wu, “A review of current progress in triple-negative breast cancer therapy,” Open Medicine, vol. 15, no. 1, pp. 1143–1149, 2020.

[7] S. Y. Hwang, S. Park, and Y. Kwon, “Recent therapeutic trends and promising targets in triple negative breast cancer,” Pharmacology & Therapeutics, vol. 199, pp. 30–57, 2019.

[8] H. A. Azim, M. Ghosn, K. Oualla, and L. Kassem, “Personalized treatment in metastatic triple-negative breast cancer: the outlook in 2020,” The Breast Journal, vol. 26, no. 1, pp. 69–80, 2020.

[9] M. K. Srour, B. Gao, F. Dadmanesh et al., “Gene expression comparison between primary triple-negative breast cancer and paired axillary and sentinel lymph node metastasis,” The Breast Journal, vol. 26, no. 5, pp. 904–910, 2020.

[10] M. M. Galvez, J. A. Jimenez, J. I. Gil Izquierdo et al., “Ultrasound staging in breast cancer: a decision-making oriented approach to axillary metastatic burden prediction,” Surgical Oncology, vol. 35, pp. 114–119, 2020.

[11] Q. Guo, Z. Dong, L. Zhang et al., “Ultrasound features of breast cancer for predicting axillary lymph node metastasis,” Journal of Ultrasound in Medicine, vol. 37, no. 6, p. 1354, 2018.

[12] Y. Luo, C. Zhao, Y. Gao et al., “Predicting axillary lymph node status with a nomogram based on breast lesion ultrasound features: performance in N1 breast cancer patients,” Frontiers in Oncology, vol. 10, article 581321, 2020.

[13] Q. Zong, J. Deng, W. Ge, J. Chen, and D. Xu, “Establishment of simple nomograms for predicting axillary lymph node involvement in early breast cancer,” Cancer Management and Research, vol. 12, pp. 2025–2035, 2020.

[14] N. S. Tucker, A. E. Cyr, F. O. Ademuyiwa et al., “Axillary ultrasound accurately excludes clinically significant lymph node disease in patients with early stage breast cancer,” Annals of Surgery, vol. 264, no. 6, pp. 1098–1102, 2016.

[15] L. W. Du, H. L. Liu, H. Y. Gong et al., “Adding contrast-enhanced ultrasound markers to conventional axillary ultrasound improves specificity for predicting axillary lymph node metastasis in patients with breast cancer,” The British Journal of Radiology, vol. 94, no. 1118, article 20200874, 2021.